Rhenman & Partners Asset Management AB reduced its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 57.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,900 shares of the medical instruments supplier's stock after selling 64,600 shares during the period. Rhenman & Partners Asset Management AB's holdings in Becton, Dickinson and Company were worth $10,867,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Resona Asset Management Co. Ltd. bought a new stake in Becton, Dickinson and Company in the fourth quarter valued at $20,930,000. PAX Financial Group LLC bought a new stake in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $212,000. Thoroughbred Financial Services LLC grew its holdings in Becton, Dickinson and Company by 15.0% in the 4th quarter. Thoroughbred Financial Services LLC now owns 4,976 shares of the medical instruments supplier's stock worth $1,129,000 after buying an additional 649 shares in the last quarter. Atlas Capital Advisors Inc. grew its stake in shares of Becton, Dickinson and Company by 28,500.0% in the fourth quarter. Atlas Capital Advisors Inc. now owns 2,860 shares of the medical instruments supplier's stock worth $649,000 after purchasing an additional 2,850 shares in the last quarter. Finally, Arete Wealth Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 5.4% during the fourth quarter. Arete Wealth Advisors LLC now owns 3,373 shares of the medical instruments supplier's stock valued at $763,000 after purchasing an additional 174 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the transaction, the director now directly owns 36,033 shares of the company's stock, valued at approximately $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 597 shares of the company's stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the sale, the executive vice president now directly owns 5,544 shares in the company, valued at $1,311,211.44. This represents a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,196 shares of company stock valued at $962,685 in the last 90 days. 0.36% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Stock Performance
Becton, Dickinson and Company stock traded down $12.43 during trading hours on Thursday, reaching $196.92. 1,136,526 shares of the company were exchanged, compared to its average volume of 1,671,995. The firm has a market cap of $56.54 billion, a price-to-earnings ratio of 32.72, a PEG ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12 month low of $193.03 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average of $225.75 and a 200 day moving average of $230.36.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's management believes its stock is undervalued.
Becton, Dickinson and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Monday, March 10th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.11%. The ex-dividend date was Monday, March 10th. Becton, Dickinson and Company's payout ratio is presently 69.10%.
Wall Street Analysts Forecast Growth
BDX has been the topic of a number of research analyst reports. Barclays lowered their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a report on Tuesday, January 28th. Finally, StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $275.71.
View Our Latest Analysis on Becton, Dickinson and Company
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
